HC Wainwright Lowers DBV Technologies (NASDAQ:DBVT) Price Target to $5.00

DBV Technologies (NASDAQ:DBVT) had its price target reduced by research analysts at HC Wainwright from $10.00 to $5.00 in a note issued to investors on Wednesday, Benzinga reports. The firm presently has a “buy” rating on the stock.

Separately, StockNews.com assumed coverage on DBV Technologies in a research report on Monday. They issued a “hold” rating for the company.

DBV Technologies Trading Up 5.1 %

DBV Technologies stock traded up $0.04 during midday trading on Wednesday, reaching $0.72. 157,517 shares of the stock traded hands, compared to its average volume of 48,438. The firm has a fifty day moving average price of $0.75 and a two-hundred day moving average price of $0.84. DBV Technologies has a fifty-two week low of $0.65 and a fifty-two week high of $2.37. The firm has a market cap of $137.90 million, a price-to-earnings ratio of -1.73 and a beta of 0.73.

DBV Technologies (NASDAQ:DBVT) last announced its earnings results on Thursday, March 7th. The company reported ($0.06) earnings per share for the quarter, beating the consensus estimate of ($0.16) by $0.10. The firm had revenue of $8.88 million for the quarter, compared to the consensus estimate of $1.10 million. DBV Technologies had a negative return on equity of 46.33% and a negative net margin of 461.32%. During the same quarter in the previous year, the business earned ($0.23) EPS. Analysts anticipate that DBV Technologies will post -0.88 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Cowen AND Company LLC purchased a new position in shares of DBV Technologies during the 4th quarter valued at $49,000. Optiver Holding B.V. grew its stake in DBV Technologies by 595.2% in the third quarter. Optiver Holding B.V. now owns 274,874 shares of the company’s stock valued at $374,000 after purchasing an additional 235,337 shares in the last quarter. Finally, Landscape Capital Management L.L.C. acquired a new position in DBV Technologies in the 3rd quarter worth about $94,000. Hedge funds and other institutional investors own 71.74% of the company’s stock.

DBV Technologies Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.